EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stereotactic Body Radiotherapy for Oligometastatic Disease in Melanoma Patients Receiving Immunotherapy: A Single-Center Retrospective Analysis

Matea Lekić, Hrvoje Kaučić iD, Domagoj Kosmina iD, Ivan Prološčić iD, Giovanni Ursi, Vanda Leipold iD, Sunčana Divošević iD, Maja Karaman Ilić iD, Karla Schwarz, Dragan Schwarz, Damir Vučinić iD

Cancers · 01.06.2026 · 18 (11) · 1812

DOI: 10.3390/cancers18111812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 01.06.2026. Verfasst von Matea Lekić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Specialty Hospital Radiochirurgia Zagreb, 10431 Sveta Nedelja, Croatia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metastatic melanoma increasingly includes clinical scenarios in which metastasis-directed treatment may complement systemic immunotherapy, particularly in oligometastatic disease. We evaluated outcomes of stereotactic body radiotherapy (SBRT) combined with immunotherapy in patients with metastatic melanoma, focusing on local control, survival, treatment sequencing, and safety.

Methods

In this retrospective single-center study, 63 patients underwent SBRT for 97 extracranial metastatic lesions while receiving immune checkpoint inhibitors. The primary endpoint was local control (LC), while secondary endpoints included progression-free survival (PFS), overall survival (OS), and treatment-related toxicity.

Results

LC rates at 12, 24, and 36 months were 95.9%, 89.7%, and 89.7%, respectively, demonstrating durable long-term control of treated lesions. Median OS was 47 months, while median PFS was not reached. A numerical trend toward longer PFS was observed among patients receiving SBRT during immunotherapy, although the differences were not statistically significant. No significant differences in LC were identified across oligometastatic disease subcategories. Combined treatment was well tolerated, with predominantly low-grade toxicity and no signal of increased immune-related adverse events.

Conclusions

SBRT combined with immunotherapy appears to be a feasible and effective metastasis-directed treatment strategy in selected patients with metastatic melanoma. Durable local control, encouraging survival outcomes, and favorable tolerability support further prospective studies to optimize treatment sequencing and the integration of local and systemic therapies.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapymelanomaoligometastatic diseaseradioimmunotherapystereotactic body radiotherapy

Autor:innen und Institutionen

  • Specialty Hospital Radiochirurgia Zagreb, 10431 Sveta Nedelja, Croatia.
  • Department of Physics, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.
  • Medical Faculty Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
  • Faculty of Health Studies, University of Rijeka, 51000 Rijeka, Croatia.
  • Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
  • Medical Faculty, Juraj Dobrila University of Pula, 52100 Pula, Croatia.

ORCID-Profile: Hrvoje Kaučić, Domagoj Kosmina, Ivan Prološčić, Vanda Leipold, Sunčana Divošević, Maja Karaman Ilić, Damir Vučinić

Zitieren

APA

Lekić, M., Kaučić, H., Kosmina, D., Prološčić, I., Ursi, G., Leipold, V., Divošević, S., Ilić, M. K., Schwarz, K., Schwarz, D., & Vučinić, D. (2026). Stereotactic Body Radiotherapy for Oligometastatic Disease in Melanoma Patients Receiving Immunotherapy: A Single-Center Retrospective Analysis. Cancers, 18(11), 1812. https://doi.org/10.3390/cancers18111812

Vancouver

Lekić M, Kaučić H, Kosmina D, Prološčić I, Ursi G, Leipold V, et al. Stereotactic Body Radiotherapy for Oligometastatic Disease in Melanoma Patients Receiving Immunotherapy: A Single-Center Retrospective Analysis. Cancers. 2026;18(11):1812. doi:10.3390/cancers18111812

BibTeX
@article{Leki2026,
  author = {Lekić, Matea and Kaučić, Hrvoje and Kosmina, Domagoj and Prološčić, Ivan and Ursi, Giovanni and Leipold, Vanda and Divošević, Sunčana and Ilić, Maja Karaman and Schwarz, Karla and Schwarz, Dragan and Vučinić, Damir},
  title = {Stereotactic Body Radiotherapy for Oligometastatic Disease in Melanoma Patients Receiving Immunotherapy: A Single-Center Retrospective Analysis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1812},
  doi = {10.3390/cancers18111812}
}
Kostenlos starten →